Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jing Christine Ye"'
Autor:
Ying S. Zou, Melanie Klausner, Jen Ghabrial, Victoria Stinnett, Patty Long, Laura Morsberger, Jaclyn B. Murry, Katie Beierl, Christopher D. Gocke, Rena R. Xian, Kevin H. Toomer, Jing Christine Ye, Robert Z. Orlowski, Carol Ann Huff, Syed Abbas Ali, Philip H. Imus, Christian B. Gocke, Guilin Tang
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/cab7ab5369954ec9946ccb2755f77a59
Autor:
Cyrille Touzeau, Carolina Schinke, Monique Minnema, Niels W.C.J. van de Donk, Paula Rodríguez-Otero, Maria-Victoria Mateos, Leo Rasche, Jing Christine Ye, Deeksha Vishwamitra, Xuewen MA, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna Goldberg, Christoph Heuck, Ajai Chari
Publikováno v:
HemaSphere, Vol 7, p e5955094 (2023)
Externí odkaz:
https://doaj.org/article/210ee6a6b6b3433f9f01f65c5a97addf
Autor:
Hans C. Lee, Naresh Bumma, Joshua Richter, Madhav Dhodapkar, James E. Hoffman, Attaya Suvannasankha, Jeffrey Zonder, Mansi R. Shah, Suzanne Lentzsch, Joseph J. Maly, Jing Christine Ye, Ka Lung Wu, Michelle Deveaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn Kroog, Yariv Houvras, Sundar Jagannath
Publikováno v:
HemaSphere, Vol 7, p e1610068 (2023)
Externí odkaz:
https://doaj.org/article/ebffe14a73ae40d0a1f44b84269e2dd0
Autor:
Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Eric Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Steve Peterson, Luciano Costa
Publikováno v:
HemaSphere, Vol 7, p e9013721 (2023)
Externí odkaz:
https://doaj.org/article/02f069b214a04cda8cb4f60e939d825c
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-13 (2022)
Abstract Background Immune checkpoint inhibitors have revolutionized cancer therapeutic paradigm and substantially improved the survival of patients with advanced malignancies. However, a significant limitation is the wide variability in clinical res
Externí odkaz:
https://doaj.org/article/ad3d6329a83e458fba6e2335bf93a9f6
Autor:
Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, Delong Liu
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-25 (2021)
Abstract Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BC
Externí odkaz:
https://doaj.org/article/4ad506c0875b4ed5a13225f361e23156
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Externí odkaz:
https://doaj.org/article/45a51a92121142e0b46119ce951d412d
Autor:
Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho
Publikováno v:
Blood. 140:4434-4435
Autor:
Matthew J. Pianko, Erica L. Campagnaro, Bernard L. Marini, Emily K Hoylman, Anna Brown, Jing Christine Ye, Victoria R Nachar, Anthony J. Perissinotti
Publikováno v:
Leukemia & Lymphoma. 61:691-698
Daratumumab and elotuzumab have demonstrated improvements in overall response rates (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM). There is a lack of comparative clinical trials and an even larger lack of co
Publikováno v:
Biomarker research. 10(1)
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapeutic paradigm and substantially improved the survival of patients with advanced malignancies. However, a significant limitation is the wide variability in clinical response.Main